Elicio Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
451 D St Fl 5 Ste 501, Boston, Massachus...Phone Number
(857) 209-0050Website
www.elicio.comRevenue
$38.2 MillionStock Symbol
ELTXIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
2
2
1
1
1
About Elicio Therapeutics
Founded in 2011, Elicio Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases.Explore more
Elicio Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Elicio Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Elicio Therapeutics
Check if Elicio Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Check out if Elicio Therapeutics is spiking on competitors!
Product Launch: Get notified when Elicio Therapeutics launches new products
Elicio Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Elicio Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once Elicio Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Elicio Therapeutics had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Elicio Therapeutics
Find more new buyers
Compare Similar Companies to Elicio Therapeutics
Compare insights from companies similar to Elicio Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$123.9M
51-200
Public
$462.1M
1994
TC
Tracy ClementeChief People Officer & Chief Human Resources Officer
Company Profile Activity
Activity Insights
Elicio Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Elicio Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Elicio Therapeutics.
Elicio Therapeutics financials insights
Gather financial insights about Elicio Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Series A
$30M
2021
Series B
$73M
2024
Share Placement
$6M
2025
Other Financing Round
$10M
Elicio Therapeutics Tech Stack
A closer look at the technologies used by Elicio Therapeutics
Most Recent Scoops
Project
Elicio Therapeutics has proposed that ELI-002 may induce durable KRAS-specific T cells that persist beyond initial treatment, modulate the tumor microenvironment, and broaden immune attack through antigen spreading to additional mutated proteins beyond KRAS, with subsequent checkpoint inhibitor therapy potentially releasing the brakes on these primed immune responses to produce deeper antitumor activity. This hypothesis is driving the company's translational analyses and prospective clinical development strategy.
Medical Research, Pharmaceuticals
Project
Elicio Therapeutics has designed the AMPLIFY Metastatic trial to prospectively evaluate the combination of ELI-002 7P, chemotherapy, and PD-1 inhibition in both recurrent and treatment-naive metastatic pancreatic ductal adenocarcinoma patients, with the study structured as a modular platform to enable rapid data generation and expansion to additional cohorts evaluating ELI-002 combinations over time, subject to funding.
Clinical Operations
Project
Elicio Therapeutics has noted that the nivolumab-inclusive treatment approach observed in the three University of Miami AMPLIFY-7P patients was not standard practice and represents the first reported use of this regimen in this context, with the current patient denominator standing at three and other AMPLIFY-7P investigators now informed of the findings, with additional sites positioned to follow the same approach as future patients experience relapse.
Medical Research
Project
Elicio Therapeutics has indicated, based on preclinical observations, that ELI-002 is planned to be administered first in the combination regimen to prime T cells prior to the initial dose of checkpoint inhibition, followed by a maintenance period to sustain immune surveillance, with further protocol details to be communicated following finalization with investigators and FDA submission.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Medical Research, Clinical Operations
Elicio Therapeutics News & Media
Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering
BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that it has entered into a definitive securities purchase agreement led by two new fundamental institutional investors with participation from a large existing shareholder for the purchase of an aggregate of 4,380,313 shares of its common stock pursuant to a registElicio Therapeutics Added to Russell 2000® and Russell 3000® Indexes
BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that the Company was added to the Russell 2000® and Russell 3000® Indexes, effective after the U.S. market close on June 26, 2026, as part of the 2026 Russell indexes annual reconstitution.Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer
BOSTON, Mass., June 17, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today reported preliminary clinical observations which the Company believes support the evaluation of ELI-002 7P in combination with checkpoint inhibition. The Company also announced plans to conduct a Phase 1 study in first-line metastatic mKRAS PDAC, subject to funding. IElicio Therapeutics Investigation Initiated: SueWallSt Investigates the Officers and Directors of Elicio Therapeutics (ELTX)
Elicio Therapeutics reported Q1 2026 results showing a widening net loss and zero revenue days before its lead clinical program failed -- investors who bought ELTX lost 72.5% in a single session. NEW YORK, June 16, 2026 /PRNewswire/ -- Elicio Therapeutics (NASDAQ: ELTX) investors lost...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Elicio Therapeutics
Sign Up For FreeTo access detailed company insights
Founded in 2011, Elicio Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases.... Read More
